dexamethasone + granisetron + palonosetron

This is a combination regimen consisting of three drugs—dexamethasone, granisetron, and palonosetron—used primarily for the prevention of chemotherapy-induced nausea and vomiting (CINV). - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressant properties. It enhances the antiemetic efficacy of 5-HT3 receptor antagonists when used in combination. - **Granisetron** is a first-generation selective serotonin (5-HT3) receptor antagonist that blocks serotonin action at 5-HT3 receptors in the central nervous system and gastrointestinal tract, thereby preventing emesis. - **Palonosetron** is a second-generation 5-HT3 receptor antagonist with a longer half-life than other agents in its class, providing extended protection against both acute and delayed CINV[1][4][5]. This triple-drug regimen may be used as an alternative to regimens containing NK1 receptor antagonists (such as aprepitant or fosaprepitant), particularly for patients receiving highly emetogenic chemotherapy regimens like anthracycline/cyclophosphamide-based therapies[1][4]. The rationale for combining two different 5-HT3 antagonists (granisetron and palonosetron) with dexamethasone would be to maximize blockade of serotonergic pathways involved in nausea/vomiting; however, this specific three-drug combination is not standard per major guidelines, which typically recommend one 5-HT3 antagonist plus dexamethasone ± an NK1 antagonist.